Novavax, Inc. (NASDAQ:NVAX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

NVAX has been the subject of a number of other research reports. Cantor Fitzgerald set a $2.00 price target on Novavax and gave the stock a “hold” rating in a research report on Monday, May 8th. ValuEngine cut Novavax from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Ladenburg Thalmann Financial Services upgraded Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price for the company in a research report on Wednesday, August 9th. Zacks Investment Research upgraded Novavax from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Saturday, June 10th. Finally, Chardan Capital reiterated a “neutral” rating and set a $1.50 target price on shares of Novavax in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Novavax has a consensus rating of “Hold” and a consensus target price of $5.24.

Shares of Novavax (NVAX) traded up 3.18% during mid-day trading on Monday, hitting $1.03. The stock had a trading volume of 3,836,483 shares. The stock’s 50-day moving average is $1.14 and its 200 day moving average is $1.14. The company’s market cap is $298.60 million. Novavax has a 12 month low of $0.73 and a 12 month high of $8.49.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The business’s quarterly revenue was up 168.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.29) earnings per share. On average, equities research analysts forecast that Novavax will post ($0.62) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Novavax, Inc. (NVAX) Lifted to “Hold” at BidaskClub” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/novavax-inc-nvax-lifted-to-hold-at-bidaskclub/1488292.html.

Several hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC boosted its position in Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 21,639 shares in the last quarter. Northern Trust Corp boosted its position in Novavax by 2.8% in the second quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company’s stock valued at $3,883,000 after buying an additional 92,854 shares in the last quarter. GSA Capital Partners LLP boosted its position in Novavax by 38.7% in the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock valued at $1,944,000 after buying an additional 471,347 shares in the last quarter. Profund Advisors LLC boosted its position in Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 455 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its position in Novavax by 555.1% in the second quarter. Nationwide Fund Advisors now owns 1,024,020 shares of the biopharmaceutical company’s stock valued at $1,178,000 after buying an additional 867,700 shares in the last quarter. Hedge funds and other institutional investors own 50.49% of the company’s stock.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.